Published in Int J Cancer on January 15, 2009
MAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancer. PLoS One (2011) 0.97
Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients. PLoS One (2011) 0.92
High expression of testes-specific protease 50 is associated with poor prognosis in colorectal carcinoma. PLoS One (2011) 0.92
Tumor-infiltrating lymphocytes and hepatocellular carcinoma: pathology and clinical management. Int J Clin Oncol (2010) 0.90
Gene expression profiling using nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy. Clin Cancer Res (2013) 0.89
Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area. Br J Cancer (2015) 0.86
Combined cancer testis antigens enhanced prediction accuracy for prognosis of patients with hepatocellular carcinoma. Int J Clin Exp Pathol (2015) 0.86
Cancer testis antigen OY-TES-1 expression and serum immunogenicity in colorectal cancer: its relationship to clinicopathological parameters. Int J Clin Exp Pathol (2013) 0.85
An overview of cancer/testis antigens expression in classical Hodgkin's lymphoma (cHL) identifies MAGE-A family and MAGE-C1 as the most frequently expressed antigens in a set of Brazilian cHL patients. BMC Cancer (2011) 0.84
Induction of HCA587-specific antitumor immunity with HCA587 protein formulated with CpG and ISCOM in mice. PLoS One (2012) 0.82
HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer. Br J Cancer (2014) 0.79
Therapeutic vaccines for gastrointestinal cancers. Gastroenterol Hepatol (N Y) (2011) 0.78
XAGE-1b expression is associated with the diagnosis and early recurrence of hepatocellular carcinoma. Mol Clin Oncol (2014) 0.77
[Diagnosis of tumours of the liver and the biliary tract: new tissue and serum markers]. Pathologe (2011) 0.77
The clinical value of the quantitative detection of four cancer-testis antigen genes in multiple myeloma. Mol Cancer (2014) 0.77
Establishment of MAGEC2-knockout cells and functional investigation of MAGEC2 in tumor cells. Cancer Sci (2016) 0.76
Intratumoral Heterogeneity of MAGE-C1/CT7 and MAGE-C2/CT10 Expression in Mucosal Melanoma. Biomed Res Int (2015) 0.75
The cancer/testis antigen MAGEC2 promotes amoeboid invasion of tumor cells by enhancing STAT3 signaling. Oncogene (2016) 0.75
Expression and prognostic relevance of MAGE-A3 and MAGE-C2 in non-small cell lung cancer. Oncol Lett (2017) 0.75
Correlations between the MEG-A3 gene and incidence of breast cancer. Oncol Lett (2016) 0.75
MAGE-TRIM28 complex promotes the Warburg effect and hepatocellular carcinoma progression by targeting FBP1 for degradation. Oncogenesis (2017) 0.75
Reply to: Comment on 'Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area'. Br J Cancer (2016) 0.75
Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg (2004) 55.13
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer (2005) 9.46
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med (2008) 7.80
Obesity in general elective surgery. Lancet (2003) 7.22
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 6.39
Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature (2003) 5.57
No surgical innovation without evaluation: the IDEAL recommendations. Lancet (2009) 5.57
Conversion of mature B cells into T cells by dedifferentiation to uncommitted progenitors. Nature (2007) 5.39
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia (2008) 5.22
Kidney transplantation from donors without a heartbeat. N Engl J Med (2002) 4.85
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 4.80
Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology (2009) 4.03
Playing Play-Doh to prevent postoperative liver failure: the "ALPPS" approach. Ann Surg (2012) 3.87
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol (2013) 3.68
ALPPS offers a better chance of complete resection in patients with primarily unresectable liver tumors compared with conventional-staged hepatectomies: results of a multicenter analysis. World J Surg (2014) 3.60
PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis. J Hepatol (2006) 3.50
Assessment of complications after pancreatic surgery: A novel grading system applied to 633 patients undergoing pancreaticoduodenectomy. Ann Surg (2006) 3.35
Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res (2009) 3.17
Aggravation of viral hepatitis by platelet-derived serotonin. Nat Med (2008) 3.10
Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol (2007) 3.09
Evaluation and stages of surgical innovations. Lancet (2009) 3.04
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol (2013) 3.00
Platelet-derived serotonin mediates liver regeneration. Science (2006) 2.98
New staging system and a registry for perihilar cholangiocarcinoma. Hepatology (2011) 2.89
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol (2008) 2.88
Challenges in evaluating surgical innovation. Lancet (2009) 2.86
A multicenter randomized clinical trial of primary anastomosis or Hartmann's procedure for perforated left colonic diverticulitis with purulent or fecal peritonitis. Ann Surg (2012) 2.82
FAN1 mutations cause karyomegalic interstitial nephritis, linking chronic kidney failure to defective DNA damage repair. Nat Genet (2012) 2.74
A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell (2009) 2.64
Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling. J Clin Invest (2006) 2.63
Use of severely steatotic grafts in liver transplantation: a matched case-control study. Ann Surg (2007) 2.53
What is a surgical complication? World J Surg (2008) 2.53
Chemotherapy before liver resection of colorectal metastases: friend or foe? Ann Surg (2012) 2.49
Evidence-based value of prophylactic drainage in gastrointestinal surgery: a systematic review and meta-analyses. Ann Surg (2004) 2.49
A prospective randomized study in 100 consecutive patients undergoing major liver resection with versus without ischemic preconditioning. Ann Surg (2003) 2.48
RhoE binds to ROCK I and inhibits downstream signaling. Mol Cell Biol (2003) 2.46
Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology (2004) 2.45
NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res (2006) 2.44
A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology (2003) 2.40
Protective strategies against ischemic injury of the liver. Gastroenterology (2003) 2.37
Recommendations for laparoscopic liver resection: a report from the second international consensus conference held in Morioka. Ann Surg (2015) 2.36
The comprehensive complication index: a novel continuous scale to measure surgical morbidity. Ann Surg (2013) 2.27
A conserved face of the Jagged/Serrate DSL domain is involved in Notch trans-activation and cis-inhibition. Nat Struct Mol Biol (2008) 2.22
Donor information for living donor liver transplantation: where can comprehensive information be found? Liver Transpl (2012) 2.21
Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat Genet (2005) 2.20
Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol (2007) 2.20
Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci U S A (2006) 2.19
Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg (2005) 2.18
How should transection of the liver be performed?: a prospective randomized study in 100 consecutive patients: comparing four different transection strategies. Ann Surg (2005) 2.16
Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci U S A (2003) 2.09
Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res (2011) 2.08
JunB can substitute for Jun in mouse development and cell proliferation. Nat Genet (2002) 2.07
Reliable detection of subclonal single-nucleotide variants in tumour cell populations. Nat Commun (2012) 2.06
Small-for-size syndrome after partial liver transplantation: definition, mechanisms of disease and clinical implications. Am J Transplant (2005) 2.06
Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. Clin Cancer Res (2008) 2.06
The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol (2013) 2.05
Trainee satisfaction in surgery residency programs: modern management tools ensure trainee motivation and success. Surgery (2011) 2.04
Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters. Eur Urol (2008) 2.02
Establishment of a multicolour fluorescence in situ hybridisation-based assay for subtyping of renal cell tumours. Eur Urol (2013) 2.00
Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol (2008) 2.00
In cystectomy specimens with bladder cancer whole organ embedding increases the detection rate of histopathological parameters, but not of those with prognostic significance. Virchows Arch (2015) 1.98
pVHL and GSK3beta are components of a primary cilium-maintenance signalling network. Nat Cell Biol (2007) 1.97
Definition and Classification of Intraoperative Complications (CLASSIC): Delphi Study and Pilot Evaluation. World J Surg (2015) 1.95
Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int J Oncol (2004) 1.95
Prospective evaluation of vacuum-assisted closure in abdominal compartment syndrome and severe abdominal sepsis. J Am Coll Surg (2007) 1.94
Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis. PLoS One (2010) 1.94
Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur Urol (2007) 1.89
ASPP1 and ASPP2: common activators of p53 family members. Mol Cell Biol (2004) 1.88
Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol (2006) 1.87
DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. J Hepatol (2011) 1.85
Atraumatic chylous ascites: systematic review on symptoms and causes. J Am Coll Surg (2011) 1.83
Human alveolar echinococcosis after fox population increase, Switzerland. Emerg Infect Dis (2007) 1.80
Evidence-based treatment of acute pancreatitis: a look at established paradigms. Ann Surg (2006) 1.79
From abstract to impact in cardiovascular research: factors predicting publication and citation. Eur Heart J (2012) 1.79
L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer (2007) 1.76
Superiority of small islets in human islet transplantation. Diabetes (2007) 1.76
Report of the Paris consensus meeting on expanded criteria donors in liver transplantation. Liver Transpl (2008) 1.75
The model for end-stage liver disease allocation system for liver transplantation saves lives, but increases morbidity and cost: a prospective outcome analysis. Liver Transpl (2011) 1.75
Activated Nrf2 impairs liver regeneration in mice by activation of genes involved in cell-cycle control and apoptosis. Hepatology (2014) 1.73
Novel and simple preoperative score predicting complications after liver resection in noncirrhotic patients. Ann Surg (2010) 1.73
Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. J Hepatol (2010) 1.73
pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. EMBO J (2008) 1.72
FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours. Eur Urol (2007) 1.72
Rhabdomyosarcoma development in mice lacking Trp53 and Fos: tumor suppression by the Fos protooncogene. Cancer Cell (2003) 1.71
The impact of complications on costs of major surgical procedures: a cost analysis of 1200 patients. Ann Surg (2011) 1.69
Early survival and safety of ALPPS: first report of the International ALPPS Registry. Ann Surg (2014) 1.69
Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol (2006) 1.69
Laparoscopic Roux-en-Y gastric bypass, but not rebanding, should be proposed as rescue procedure for patients with failed laparoscopic gastric banding. Ann Surg (2003) 1.67
Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study. Ann Surg Oncol (2009) 1.67